Drug Use Evaluation of Three Widely Prescribed Antibiotics in a
Abstract
Background: Drug utilization studies are helpful in understanding the current practice. We have conducted a retrospective study to evaluate the relevant use of a group of most commonly prescribed antibiotics in a teaching hospital in Iran. The results of this study may be of help for clinicians to improve the patient care.
Methods: Patients who received parenteral ceftazidim, vancomycin and amikacin from December2010 to May 2011 were enrolled in this study. Patient’s data including demographic, length of Hospital stay, drug allergy, first and final diagnosis were recorded in a predesigned data collection form. American Hospital Formulary Services (AHFS) book were used as a reference for evaluation of study drug indication and dosing according to diagnosis and microbiological culture. Defined Daily Dose (DDD) of each drug extracted from Anatomic and Therapeutic Chemical classification system (ATC/DDD) and drug usage data evaluated by calculating the ratio of prescribed drug to its DDD.|
Results: The ratio of prescribed daily dose to DDD was 0.78, 0.95 and 0.86 for amikacin, ceftazidime and vancomycin respectively. Between amikacin group, 43 patients (86%) received drug empirically, the number of empiric treatments for ceftazidim and vancomycin were 45(90%) and 44 patients (88%). The renal function tests (Blood Urea Nitrogen, Serum Creatinin) were evaluated in 56% of amikacin group, 64% in ceftazidime group and 78% in vancomycin group.
Conclusion: The results of this study indicate the need to establish continuing medical education (CME) courses for physicians to familiarize them with standards required to use and monitor these agents.
Buke AC, Ermertcan S, Hosgor-Limoncu M. Rational antibiotic use and academic staff. Int J Antimicrob Ag 2003;21(1): 63-66.
Alanis AJ. Resistance to antibiotics: are we in the post-antibiotic era? Arch Med Res 2005; 36(6): 697-705.
Von Gunten V, Reymond JP, Boubaker K. Antibiotic use: is appropriateness expensive? J Hosp Infect 2009;71(2): 108-11.
McEvoy GK American Society of Health-System Pharmacists., AHFS Drug information 2011, Bethesda, Md.: American Society of Health- System Pharmacists. p 3824.
WHO. Collaborating Center for Drug Statistics Methodology. ATC Index with DDDs.2000, 2012-12-20.
Hsueh PR, Chen WH, Luh KT. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents 2005;26(6): 463-72.
Freeman CD, Nicolau DP, Belliveau PP. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997;39(6): 677-86.
Vazin A, Japoni A, Shahbazi S. Vancomycin Utilization Evaluation at Hematology-Oncology Ward of a Teaching Hospital in Iran. IJPR 2012;1(11): 163-70.
Khalili H, Gholami K, Hajiabdolbaghi M, Sairafipoor Z. Vancomycin Drug Utilization Evaluation (DUE) in infectious disease ward of Imam Khomeini Hospital. Tehran Univ Med J 2006; 64 (12) :64-8
Junior MS, Correa L, Marra AR. Analysis of vancomycin use and associated risk factors in a university teaching hospital: a prospective cohort study. BMC Infectious Diseases 2007;7: 88.
Mandell LA,Wunderink RG, Anzueto A. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 (Suppl 2): S27-72.
Tunkel AR, Hartman BJ, Kaplan SL. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39(9): 1267- 84.
| Files | ||
| Issue | Vol 1، No 3 (Summer 2013) | |
| Section | Original Article(s) | |
| Keywords | ||
| Drug Utilization Evaluation Amikacin Ceftazidime Vancomycin | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
